<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevalence and thrombosis risk for selected thrombophilias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevalence and thrombosis risk for selected thrombophilias</h1>
<div class="graphic"><div class="figure"><div class="ttl">Prevalence and thrombosis risk for selected thrombophilias</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Thrombophilia</td> <td class="subtitle1">Prevalence</td> <td class="subtitle1">Relative risk (absolute annualized risk) of initial VTE*</td> <td class="subtitle1">Relative risk of recurrent VTE</td> <td class="subtitle1">Relative risk (absolute annualized risk) of initial VTE, OCP users*<sup>¶</sup></td> <td class="subtitle1">Relative risk (absolute annualized risk) of initial VTE, HRT users*<sup>¶</sup><sup>Δ</sup></td> <td class="subtitle1">Absolute risk of VTE in pregnancy*</td> </tr> <tr> <td>FVL heterozygous</td> <td>2 to 7%</td> <td>3.48 to 5.51 (0.05 to 0.2%)</td> <td>1.1 to 1.8</td> <td>2.47 to 15.04 (0.1 to 0.6%)</td> <td>1.4 to 13.16 (1.6 to 5.97%)</td> <td>0.5% at age &lt;35,<br/> 0.7% at age ≥35</td> </tr> <tr class="highlight_lght_gray_text"> <td>FVL homozygous</td> <td>0.06 to 0.25%</td> <td>6.79 to 19.29 (0.8%)</td> <td>1.8</td> <td>Uncertain</td> <td>Uncertain</td> <td>2.2% at age &lt;35,<br/> 3.4% at age ≥35</td> </tr> <tr> <td>PGM heterozygous</td> <td>1 to 2%</td> <td>2.25 to 3.48 (0.13%)</td> <td>0.7 to 2.3</td> <td>3.60 to 8.63</td> <td>(2.85%)</td> <td>0.4% at age &lt;35,<br/> 0.6% at age ≥35</td> </tr> <tr class="highlight_lght_gray_text"> <td>PGM homozygous</td> <td>Rare</td> <td>2.19 to 20.72</td> <td>Uncertain</td> <td>Uncertain</td> <td>Uncertain</td> <td>Not available</td> </tr> <tr> <td>Compound FVL and PGM heterozygosity</td> <td>0.1%</td> <td>1.13 to 5.04 (0.42%)</td> <td>2.7</td> <td>3.79 to 76.47 (0.17%)</td> <td>Uncertain</td> <td>5.5% at age &lt;35,<br/> 8.2% at age ≥35</td> </tr> <tr class="highlight_lght_gray_text"> <td>PC deficiency</td> <td>0.2 to 0.5%</td> <td>10 (0.4 to 2.3%)</td> <td>1.8</td> <td>1.7 to 23.9 (1.7 to 7.1%)</td> <td>(2.96%)</td> <td>0.7% at age &lt;35,<br/> 1.1% at age ≥35</td> </tr> <tr> <td>PS deficiency</td> <td>0.1 to 0.7%</td> <td>9.6 (0.7 to 3.2%)</td> <td>1.0</td> <td>1.4 to 17.1 (1.3 to 2.4%)</td> <td>(2.3%)</td> <td>0.7% at age &lt;35,<br/> 1.0% at age ≥35</td> </tr> <tr class="highlight_lght_gray_text"> <td>AT deficiency</td> <td>0.02%</td> <td>10 to 30 (1.2 to 4.4%)</td> <td>2.6</td> <td>1.4 to 115.8 (2.5 to 5.1%)</td> <td>(5.73%)</td> <td>6.1% at age &lt;35,<br/> 9.0% at age ≥35</td> </tr> <tr> <td>APS</td> <td>2%</td> <td>7</td> <td>1.5 to 6.8</td> <td>0.3 to 3.1</td> <td>(1.05 to 2.63%)</td> <td>15.8</td> </tr> </tbody></table></div><div class="graphic_lgnd">Individuals with the following thrombophilias are considered at high risk for VTE: AT deficiency, homozygotes for FVL, homozygotes for prothrombin G20210A (PGM), and double heterozygotes for FVL and PGM.</div><div class="graphic_footnotes"><p>VTE: venous thromboembolism; OCP: oral contraceptive pill (containing estrogen); HRT: hormone replacement therapy (containing estrogen); FVL: factor V Leiden; PGM: prothrombin gene G20210A mutation; PC: protein C; PS: protein S; AT: antithrombin; APS: antiphospholipid syndrome.</p>
<p>* Data are taken from reference 14; therefore, absolute rates may differ from the other sources since calculations are based on prevalence and relative risk.<sup>[1-13]</sup></p>
<p>¶ Relative risks are compared with nonusers without thrombophilia.</p>
    Δ With the exception of heterozygous FVL, estimates are based on modeling rather than epidemiologic studies.</div><div class="graphic_reference">References:
<ol>
<li>Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293:2352.</li>
<li>Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121:458.</li>
<li>Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol 2013; 28:621.</li>
<li>Mahmoodi BK, Brouwer JL, Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 2010; 8:1193.</li>
<li>Pernod G, Biron-Andreani C, Morange PE, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009; 34:156.</li>
<li>Merriman L, Greaves M. Testing for thrombophilia: an evidence-based approach. Postgrad Med J 2006; 82:699.</li>
<li>Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost effectiveness analysis. Br J Haematol 2005; 131:80.</li>
<li>Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Chest 2012; 141:e691S.</li>
<li>Lindhoff-Last E, Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 2008; 37:19.</li>
<li>Cohen W, Castelli C, Suchon P, et al. Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseilles-NImes prediction model. J Thromb Haemost 2014; 12:138.</li>
<li>Davis SM, Branch DW. Thromboprophylaxis in pregnancy: who and how? Obstet Gynecol Clin North Am 2010; 37:333.</li>
<li>Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol 2009; 114:341.</li>
<li>Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94:17.</li>
<li>Gerhardt A, Scharf RE, Greer IA, Zotz RB. Hereditary risk factors of thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood 2016; 128:2343.</li>
</ol>
<p class="extra_spacing_top">From: Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 2016; 41:154. Available at: <a href="https://link.springer.com/article/10.1007%2Fs11239-015-1316-1" target="_blank">https://link.springer.com/article/10.1007%2Fs11239-015-1316-1</a>. Copyright © 2016 Stevens SM, Woller SC, Bauer KA, et al. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License</a> 4.0.</p></div><div id="graphicVersion">Graphic 119942 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
